Exicure, Inc. Reports Second Quarter 2025 Financial Results

How might the reported results influence short‑term technical trends and trading volume for EXC? What is the impact of the Q2 results on the stock's valuation multiples (e.g., P/E, EV/EBITDA) relative to industry peers? How does Exicure's Q2 performance stack up against its main competitors in the biotech sector? What were the drivers behind any significant changes in operating expenses or R&D spending? What was the year‑over‑year growth rate for key financial metrics such as revenue, net income, and operating cash flow? Are there any macro‑economic or sector‑specific factors that could amplify or mitigate the effect of these earnings on the stock? Did the results include any major partnership announcements, licensing deals, or regulatory milestones that could affect future growth? Did the company provide any guidance or outlook for Q3 2025 or the full‑year 2025? Are there any notable changes in the company's capital structure, such as debt issuance or equity repurchases? How did Exicure's Q2 2025 revenue compare to analysts' expectations?